Avicanna Inc represents a strong commitment to innovation, integrity, and sustainability. With its focus on the development and commercialization of plant-derived pharmaceuticals, Avicanna aims to provide advanced medical solutions using cannabinoid-based therapies. The company's corporate philosophy is centered on rigorous scientific research, stringent quality control standards, and ethical practices throughout its operations. Avicanna's dedication to collaboration with healthcare professionals, regulatory compliance, and patient-centric care underscores its mission to enhance the lives of individuals with unmet medical needs. Through its pioneering efforts, Avicanna Inc strives to redefine the future of cannabinoid-based medicines.

Avicanna Inc is primarily present in Canada, Colombia, and Jamaica.

Avicanna Inc has achieved several significant milestones in its history. Firstly, the company successfully attained a license from the Colombian government for the cultivation of psychoactive cannabis plants. In addition, Avicanna has established strategic partnerships with leading academic institutions, such as the University of Toronto, to conduct extensive scientific research on cannabinoids. The company has also developed several innovative pharmaceutical and dermacosmetic products, leveraging its expertise in cannabinoid-based therapies. Avicanna Inc has gained international recognition for its high-quality products and innovative research, positioning itself as a prominent player in the global cannabis industry.

Avicanna Inc is a renowned Canadian biopharmaceutical company. Founded in 2016, Avicanna specializes in the development and commercialization of plant-derived cannabinoid-based products. With a mission to harness the therapeutic potential of cannabinoids, Avicanna leverages its scientific expertise in evidence-based research, pharmaceutical development, and cultivation techniques. The company operates globally and maintains partnerships with various academic institutions and multinational organizations to advance its innovations. Avicanna is recognized for its vertically integrated approach, ensuring quality control from cultivation to end products, which include pharmaceuticals, skincare, and nutraceuticals. With a commitment to scientific excellence, Avicanna remains at the forefront of the rapidly expanding cannabis industry.

Some of the main competitors of Avicanna Inc in the market include Canopy Growth Corporation, Aurora Cannabis Inc, and Cronos Group Inc. These companies are also actively engaged in the cannabis industry and operate in similar markets as Avicanna Inc.

Avicanna Inc is primarily active in the cannabis and pharmaceutical industries.

Avicanna Inc's business model revolves around the development and commercialization of pharmaceutical-grade cannabinoid-based products. The company focuses on harnessing the therapeutic potential of cannabinoids through research, collaboration, and strategic partnerships. Avicanna aims to offer innovative solutions for various medical conditions by leveraging their expertise in pharmaceutical development, cultivation, extraction, and formulation technologies. Their comprehensive portfolio includes patented and patent-pending pharmaceutical-grade formulations, derma-cosmetics, and natural health products. Avicanna Inc strives to revolutionize the global medical cannabis market by providing high-quality, evidence-based medicinal products to improve patients' lives.

Det Avicanna P/E-forhold er 18,66.

Avicanna KUV er 1,74.

AlleAktien Kvalitetsscore for Avicanna er 4/10.

Den forventede Avicanna omsætning er 21,42 mio. CAD.

Den forventede Avicanna indtjening er 2,00 mio. CAD.

Avicanna Inc is a Canadian biotechnology company in the medical and recreational cannabis industry. The company is based in Toronto and focuses on researching, developing, and manufacturing plant-based products using cannabinoids. Avicanna aims to deliver innovative products to improve the lives of patients and consumers. The company currently has three main business divisions: medical products, cosmetic products, and recreational products. In the medical field, Avicanna focuses on producing medical cannabis products for the treatment of serious illnesses such as cancer, pain, and inflammation. The company has also developed products specifically designed for women with menstrual discomfort and for patients with insomnia. In addition to medical products, Avicanna has also developed a line of advanced skincare products based on cannabinoids, specifically designed for people with skin conditions. With products such as lotions, serums, and tinctures, customers in Avicanna's cosmetic division can utilize a natural alternative for skincare based on the healing properties of cannabis. In the recreational sector, Avicanna recognizes the growing demand for cannabis products and has therefore developed products for the recreational market. Avicanna's recreational products include smoked cannabis, edible products, beverages, and oils. These products are becoming increasingly popular in the cannabis industry and can be used by customers as a legal alternative to illicit drugs. Aside from its main business divisions, Avicanna has also formed partnerships and joint ventures with other companies to spread its technology and products throughout the industry. For example, a strategic partnership with Santa Marta Golden Hemp in Colombia will allow Avicanna to produce its products and technologies at a competitive cost base and enter the South American market. Avicanna's business model is to develop medical, cosmetic, and recreational cannabis products based on the natural healing properties of cannabis. The company aims to provide natural alternatives for diseases treatment and skincare, while also serving the rapidly evolving recreational cannabis industry. Avicanna also utilizes strategic partnerships to spread its technology and products within the cannabis industry.

Avicanna udbetaler et udbytte på 0 CAD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Avicanna, eller selskabet udbetaler ikke udbytte.

ISIN'en for Avicanna er CA05368K1003.

WKN for Avicanna er A2PN04.

Tickeren for Avicanna er AVCN.TO.

I løbet af de sidste 12 måneder betalte Avicanna en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Avicanna sandsynligvis betale en dividende på 0 CAD.

Udbytteafkastet for Avicanna er i øjeblikket .

Avicanna betaler kvartalsvis udbytte. Dette uddeles i månederne .

Avicanna betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 CAD. Dette svarer til et dividendeafkast på 0 %.

Avicanna bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Avicanna fra den 8.7.2024 på 0 CAD, skulle du have haft aktien i din portefølje før ex-datoen den 8.7.2024.

Udbetalingen af det sidste udbytte blev foretaget den 8.7.2024.

I løbet af 2023 udbetalte Avicanna 0 CAD i form af dividender.

Udbytterne fra Avicanna udbetales i CAD.